People: Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

1:30am IST
Change (% chg)

$0.02 (+0.47%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hanlon, Suzanne 

Ms. Suzanne M. Hanlon J.D. serves as Vice President, General Counsel, Secretary of the Company. Ms. Hanlon served as our legal consultant from May 2014 to October 2014. Ms. Hanlon has more than 25 years of legal experience in the pharmaceutical industry. Ms. Hanlon served as vice president, associate general counsel of NuPathe from July 2005 to April 2014, where she worked with Mr. Anido and Ms. Sebree on the regulatory approval of Zecuity, a transdermal patch for migraines. Prior to joining NuPathe, Ms. Hanlon served as chief development counsel of Auxilium, a specialty pharmaceutical company. Prior to joining Auxilium, Ms. Hanlon served as vice president of global contracts and general counsel at IBAH, Inc. Prior to joining IBAH, Inc., Ms. Hanlon was a partner at Montgomery McCracken Walker & Rhoads LLP. Ms. Hanlon holds a B.A. from Pennsylvania State University and a J.D. from Villanova University School of Law.

Basic Compensation

Total Annual Compensation, USD 61,538
Restricted Stock Award, USD 96,394
Long-Term Incentive Plans, USD --
All Other, USD 87,107
Fiscal Year Total, USD 245,039

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --